

Yang Meng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8074813/publications.pdf>

Version: 2024-02-01

25
papers

1,393
citations

430874

18
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

2233
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. <i>Lancet, The</i> , 2014, 383, 1655-1664.	13.7	235
2	Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2011, 37, 187-198.	1.0	112
3	Trend analysis and modelling of gender-specific age, period and birth cohort effects on alcohol abstinence and consumption level for drinkers in Great Britain using the General Lifestyle Survey 1984-2009. <i>Addiction</i> , 2014, 109, 206-215.	3.3	107
4	Estimated Effects of Different Alcohol Taxation and Price Policies on Health Inequalities: A Mathematical Modelling Study. <i>PLoS Medicine</i> , 2016, 13, e1001963.	8.4	98
5	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. <i>British Journal of Surgery</i> , 2012, 99, 1630-1638.	0.3	94
6	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2011, 15, iii-iv, 1-134.	2.8	86
7	Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: identification of consistent biases across four English-speaking countries. <i>Addiction</i> , 2016, 111, 1203-1213.	3.3	85
8	Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2011, 37, 928-936.	1.0	79
9	Estimation of own and cross price elasticities of alcohol demand in the UK: A pseudo-panel approach using the Living Costs and Food Survey 2001-2009. <i>Journal of Health Economics</i> , 2014, 34, 96-103.	2.7	68
10	Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. <i>BMJ, The</i> , 2014, 349, g5452-g5452.	6.0	54
11	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. <i>Health Technology Assessment</i> , 2011, 15, 1-210.	2.8	48
12	Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently?. <i>Addiction</i> , 2014, 109, 1994-2002.	3.3	44
13	Adjusting for Unrecorded Consumption in Survey and per Capita Sales Data: Quantification of Impact on Gender- and Age-specific Alcohol-attributable Fractions for Oral and Pharyngeal Cancers in Great Britain. <i>Alcohol and Alcoholism</i> , 2013, 48, 241-249.	1.6	41
14	The Sheffield Alcohol Policy Model - A Mathematical Description. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1368-1388.	1.7	36
15	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. <i>Health Technology Assessment</i> , 2015, 19, 1-216.	2.8	33
16	An application of agent-based simulation to the management of hospital-acquired infection. <i>Journal of Simulation</i> , 2010, 4, 60-67.	1.5	32
17	Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. <i>European Journal of Surgical Oncology</i> , 2011, 37, 40-46.	1.0	30
18	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. <i>European Journal of Health Economics</i> , 2018, 19, 1163-1172.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. <i>Angiology</i> , 2014, 65, 190-197.	1.8	18
20	A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. <i>Journal of Medical Economics</i> , 2019, 22, 205-214.	2.1	17
21	Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. <i>Annals of Operations Research</i> , 2016, 236, 149-176.	4.1	15
22	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 967-977.	2.1	13
23	Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours — an analysis based on the CLARINET study. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 131.	2.4	12
24	Estimation of usual occasion-based individual drinking patterns using diary survey data. <i>Drug and Alcohol Dependence</i> , 2014, 134, 136-143.	3.2	9
25	Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (<i>Br J Surg</i> 2012; 99: 1630–1638). <i>British Journal of Surgery</i> , 2013, 100, 1838-1839.	0.3	2